Literature DB >> 19220239

Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources.

C Dryden1, D Young, M Hepburn, H Mactier.   

Abstract

OBJECTIVES: The objectives of this study were to investigate factors associated with the development of neonatal abstinence syndrome (NAS) and to assess the implications for healthcare resources of infants born to drug-misusing women.
DESIGN: Retrospective cohort study from 1 January 2004 to 31 December 2006.
SETTING: Inner-city maternity hospital providing dedicated multidisciplinary care to drug-misusing women. POPULATION: Four hundred and fifty singleton pregnancies of drug-misusing women prescribed substitute methadone in pregnancy.
METHODS: Case note review. MAIN OUTCOME MEASURES: Development of NAS and duration of infant hospital stay.
RESULTS: 45.5% of infants developed NAS requiring pharmacological treatment. The odds ratio of the infant developing NAS was independently related to prescribed maternal methadone dose rather than associated polydrug misuse. Breastfeeding was associated with reduced odds of requiring treatment for NAS (OR 0.55, 95% CI 0.34-0.88). Preterm birth did not influence the odds of the infant receiving treatment for NAS. 48.4% infants were admitted to the neonatal unit (NNU) 40% of these primarily for treatment of NAS. The median total hospital stay for all infants was 10 days (interquartile range 7-17 days). Infants born to methadone-prescribed drug-misusing mothers represented 2.9% of hospital births, but used 18.2% of NNU cot days.
CONCLUSIONS: Higher maternal methadone dose is associated with a higher incidence of NAS. Pregnant drug-misusing women should be encouraged and supported to breastfeed. Their infants are extremely vulnerable and draw heavily on healthcare resources.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19220239     DOI: 10.1111/j.1471-0528.2008.02073.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  54 in total

1.  Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Authors:  Walter K Kraft; Kevin Dysart; Jay S Greenspan; Eric Gibson; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Addiction       Date:  2010-10-06       Impact factor: 6.526

2.  Factors associated with buprenorphine versus methadone use in pregnancy.

Authors:  Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day
Journal:  Subst Abus       Date:  2016-02-25       Impact factor: 3.716

3.  Characteristics and quality of life of opioid-dependent pregnant women in Austria.

Authors:  Verena E Metz; Sandra D Comer; Johanna Wuerzl; Anna Pribasnig; Gabriele Fischer
Journal:  Arch Womens Ment Health       Date:  2014-07-15       Impact factor: 3.633

Review 4.  The United States opioid epidemic.

Authors:  Jennifer Lyden; Ingrid A Binswanger
Journal:  Semin Perinatol       Date:  2019-01-14       Impact factor: 3.300

5.  Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature.

Authors:  Mahsa M Yazdy; Rishi J Desai; Susan B Brogly
Journal:  J Pediatr Genet       Date:  2015-04-01

6.  The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations.

Authors:  Hendrée E Jones; Lauren M Jansson; Kevin E O'Grady; Karol Kaltenbach
Journal:  Neurotoxicol Teratol       Date:  2013 Sep-Oct       Impact factor: 3.763

7.  Should pregnant women with substance use disorders be managed differently?

Authors:  Verena Metz; Birgit Köchl; Gabriele Fischer
Journal:  Neuropsychiatry (London)       Date:  2012-01-25

8.  Neonatal abstinence syndrome--postnatal ward versus neonatal unit management.

Authors:  Tolulope Saiki; Silke Lee; Simon Hannam; Anne Greenough
Journal:  Eur J Pediatr       Date:  2009-05-14       Impact factor: 3.183

9.  Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphine.

Authors:  Yao-Chang Chiang; Tsai-Wei Hung; Cynthia Wei-Sheng Lee; Jia-Ying Yan; Ing-Kang Ho
Journal:  J Biomed Sci       Date:  2010-06-07       Impact factor: 8.410

10.  Prenatal methadone exposure and neonatal neurobehavioral functioning.

Authors:  Martha L Velez; Lauren M Jansson; Jennifer Schroeder; Erica Williams
Journal:  Pediatr Res       Date:  2009-12       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.